Permission to conduct bioequivalence studies
15 December 2020
CPD has received permission from the Ministry of Health of Russia to conduct bioequivalence studies of a series of drugs.
Medications
- for the treatment of benign prostatic hyperplasia (dual 5α-reductase inhibitor)
- for the treatment of benign prostatic hyperplasia, treatment of dysuric disorders (a1-adrenergic receptor blocker)
- for the treatment of chronic paranoid and hallucinatory-paranoid states, states of psychomotor agitation in schizophrenia (neuroleptic).